Valion Bio, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Valion Bio, Inc. (VBIO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $428.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-14
- Valion Bio, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $251.00K.
- Valion Bio, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $177.00K.
- Valion Bio, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Valion Bio, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $0.00.
- Valion Bio, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Valion Bio, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $349.00K, a 100.57% increase from fiscal 2023.
- Valion Bio, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $174.00K, a 6.10% increase from fiscal 2022.
- Valion Bio, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $164.00K, a 925.00% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 1 month | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $251.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $428.00K 10-Q · filed 2026-08-14 | $428.00K derived: sum of 3 quarters · filed 2026-08-14 | $428.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $177.00K 10-Q · filed 2026-05-14 | $177.00K derived: sum of 2 quarters · filed 2026-05-14 | $177.00K derived: sum of 3 quarters · filed 2026-05-14 | $177.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $0.00 10-K · filed 2026-03-30 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $0.00 10-Q · filed 2025-11-14 | $273.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $273.00K derived: sum of 3 quarters · filed 2026-08-14 | $273.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $273.00K derived: sum of 2 quarters · filed 2026-05-14 | $273.00K derived: sum of 3 quarters · filed 2026-05-14 | $304.00K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $273.00K derived: sum of 2 quarters · filed 2026-03-30 | $304.00K derived: sum of 3 quarters · filed 2026-03-30 | $349.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $31.00K derived: sum of 2 quarters · filed 2025-11-14 | $76.00K 10-Q · filed 2025-11-14 | $121.00K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $76.00K 10-Q · filed 2025-08-14 | $121.00K derived: sum of 3 quarters · filed 2025-08-14 | $165.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $45.00K 10-Q · filed 2025-05-15 | $90.00K derived: sum of 2 quarters · filed 2025-05-15 | $134.00K derived: sum of 3 quarters · filed 2025-05-15 | $177.00K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $89.00K derived: sum of 2 quarters · filed 2025-03-21 | $132.00K derived: sum of 3 quarters · filed 2025-03-21 | $174.00K 10-K · filed 2025-03-21 | |
| 2023-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $87.00K derived: sum of 2 quarters · filed 2024-11-14 | $129.00K 10-Q · filed 2024-11-14 | $171.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $85.00K 10-Q · filed 2024-08-14 | $127.00K derived: sum of 3 quarters · filed 2024-08-14 | $169.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $42.00K 10-Q · filed 2024-05-15 | $84.00K derived: sum of 2 quarters · filed 2024-05-15 | $126.00K derived: sum of 3 quarters · filed 2024-05-15 | $166.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $84.00K derived: sum of 2 quarters · filed 2024-03-25 | $124.00K derived: sum of 3 quarters · filed 2024-03-25 | $164.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $82.00K derived: sum of 2 quarters · filed 2023-11-14 | $122.00K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $80.00K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $40.00K 10-Q · filed 2023-05-15 | ||||
| 2022-01-31 | $40.00K 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | $16.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |